RIP3 antagonizes a TSC2-mediated pro-survival pathway in glioblastoma cell death. by Fettweis, Grégory et al.
Biochimica et Biophysica Acta 1864 (2017) 113–124
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrRIP3 antagonizes a TSC2-mediated pro-survival pathway in glioblastoma
cell deathGregory Fettweis a, Emmanuel Di Valentin b, Laurent L'homme a, Cédric Lassence a, Franck Dequiedt c,
Marianne Fillet d, Isabelle Coupienne a, Jacques Piette a,⁎
a Laboratory of Virology and Immunology, GIGA-I3, University of Liège, Liège, Belgium
b GIGA-Viral Vector Platform, University of Liège, Liège, Belgium
c Laboratory of Protein Signaling and Interactions, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium
d Laboratory for the Analysis of Medicines (LAM), Department of Pharmaceutical Sciences, CIRM, University of Liège, Liège, BelgiumAbbreviations: 5-ALA, 5-aminolevulinic acid;MK2,MAP
2; p38, Mitogen-Activated Protein kinase p38; PDT, Photo
Interacting Protein; TSC, Tuberous Sclerosis; YWHA,
Tryptophan 5-Monooxygenase Activation Protein, 14-3-3 p
⁎ Corresponding author at: Laboratory of Virology a
University of Liege, 1 Avenue de l'Hôpital, Liège 4000, Bel
E-mail address: jpiette@ulg.ac.be (J. Piette).
http://dx.doi.org/10.1016/j.bbamcr.2016.10.014
0167-4889/© 2016 Published by Elsevier B.V.a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 July 2016
Received in revised form 29 September 2016
Accepted 25 October 2016
Available online 27 October 2016Glioblastomas are the deadliest type of brain cancer and are frequently associatedwith poor prognosis and a high
degree of recurrence despite removal by surgical resection and treatment by chemo- and radio-therapy.
Photodynamic therapy (PDT) is a treatment well known to induce mainly necrotic and apoptotic cell death in
solid tumors. 5-Aminolevulinic acid (5-ALA)-based PDT was recently shown to sensitize human glioblastoma
cells (LN-18) to a RIP3 (Receptor Interacting Protein 3)-dependent cell death which is counter-acted by activa-
tion of autophagy. These promising results led us to investigate the pathways involved in cell death and survival
mechanisms occurring in glioblastoma following PDT. In the present study, we describe a new TSC2 (Tuberous
Sclerosis 2)-dependent survival pathway implicating MK2 (MAPKAPK2) kinase and 14-3-3 proteins which con-
ducts to the activation of a pro-survival autophagy.Moreover, we characterized a new RIP3/TSC2 complexwhere
RIP3 is suggested to promote cell death by targeting TSC2-dependent survival pathway. These results highlight
(i) a new role of TSC2 to protect glioblastoma against PDT-induced cell death and (ii) TSC2 and 14-3-3 as new
RIP3 partners.






Glioblastomas are among the most frequent and deadliest human
brain tumors [1]. The current therapeutic strategy involves surgical re-
section combinedwith chemo- and radio-therapy [2–4]. Despite exten-
sive research, efﬁcient long-term treatments remain elusive and
glioblastomas are associatedwith a high degree of recurrence and ame-
dian of survival of 14 months. Several genetic alterations have been as-
sociated with glioblastoma, which culminate in deregulation of major
signaling pathways such as those including EGFR, p53 and over-
activation of the NF-κB and AKT/mTOR axis [5,6].
Photodynamic therapy (PDT) is a promising treatment against solid
tumors, especially glioblastoma for which this treatment is considered
now as a treatment of choice among a few neurosurgical therapeutic
opportunities [7]. This therapy relies on a photosensitizer, which upon
illumination by visible light of speciﬁc wavelength, produces a burst ofKinase-Activated Protein kinase
dynamic Therapy; RIP, Receptor
Tyrosine 3-Monooxygenase/
roteins.
nd Immunology, GIGA-R B34,
gium.ROS (Reactive Oxygen Species) that can lead to cell death. In this
study we used the 5-aminolevulinic acid (5-ALA) prodrug approach
which is known to lead to the accumulation of protoporphyrin IX
(PPIX) in mitochondria [8]. Indeed, in the heme cycle, 5-ALA is metabo-
lized in photosensitive PPIX which selectively accumulates in tumor
cells due to their low ferrochelatase levels [9]. Interestingly, this high se-
lectivity for tumor cells is frequently used for ﬂuorescence guided resec-
tion by neuro-surgeons, and notably for glioblastomas [10]. In addition,
it was shown that PDT can successfully expand the survival of patients
suffering from non-resectable glioblastoma tumors [11–13].
Previously, we showed that two antagonistic signaling pathways are
involved in PDT-induced glioblastoma cell death. First, 5-ALA-PDT in-
duces in glioblastoma a strong pro-survival autophagy via a still incom-
pletely described mechanism [14]. This autophagy process is directly
regulated by TSC2 (Tuberous Sclerosis 2), a protein known tobe regulat-
ed by phosphorylation [15], ubiquitination [16] and acetylation [17],
which associates with TSC1. The TSC2-TSC1 complex down-regulates
the mTOR complex activity, which represses the autophagy pathway
and promotes survival and proliferation [18]. As we have previously
shown, activation of mTOR downstream effectors was reduced after
PDT, suggesting a down-regulation of the mTOR complex activity and
a subsequent possible rise of the autophagic ﬂux [14]. On the other
hand, PDT is known to induce both necrosis and apoptosis in
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3 (RIP3), a key protein of the programmed necrosis pathway
(necroptosis) was demonstrated to be involved in PDT-induced glio-
blastoma cell death induced by PDT [21–23] and other cell death in-
ducers [24–26]. The current model of necroptosis relies on the
assembly of the “necrosome” complex, in which Receptor Interacting
Protein kinase 3 (RIP3) interacts with RIP1, Fas-Associated protein
with Death Domain (FADD) and Caspase-8 upon a combined treatment
of TNF-α, Smac-mimetic and pan-caspases inhibitors [27]. Unexpected-
ly, our latest data strongly suggested that the classical necrosome part-
ners of RIP3 were not present in RIP3 containing complex in LN-18
glioma cells after 5-ALA-PDT treatment [21].
In the present study, we highlight the interference between a pro-
necrotic RIP3 complex and a pro-survival TSC2-dependent pathway in
glioblastoma treated by PDT.
2. Materials and methods
2.1. Cell culture
Human glioblastoma LN18, U87-MG and U373 cell lines were a kind
gift of Pierre Robe (Human Genetics, GIGA-R, University of Liege,
Belgium). F98 cells were kindly provided by Emmanuel Garçion
(INSERM, Angers, France). T98G cell line was obtained from the ATCC.
Cells were grown in DMEM complemented with 10% fetal bovine
serum and 100 units mL−1 penicillin/streptomycin (Gibco) and main-
tained at 37 °C in a 5% CO2 humidiﬁed atmosphere.
2.2. Plasmids single site directed mutagenesis and transfections
pcDNA3.0 3XHA-TSC2 (rat) WT (24939), and pcDNA3.0 FLAG-TSC2
(human) WT (14129) [28] plasmids were purchased via the Addgene
they were deposited respectively by the Pr Kun-Liang Guan (University
of California, San Diego) and Brendan D. Manning (Harvard T.H. School
of Public Health). Control empty vector (EV) pcDNA3.0 3XHAwas gen-
erated by digestion of the plasmid 24939, with NotI, XbaI and KpnI re-
striction enzymes. pcDNA3.0 3XHA TSC2 (human) was constructed by
cloning human TSC2 from the plasmid 14129with the In-Fusion cloning
system (Clontech). The Q5 High Fidelity DNA-Polymerase (NEB) was
then used according the manufacturer to perform site directed muta-
genesis to generate 3XHA-TSC2 (rat) S1254A and P1256A; and 3XHA-
TSC2 (human) S1254A and P1256A mutants. For the establishment of
stable cell lines, target cells were cultured until 80–90% of conﬂuence
in 6-well plates and transfected with 1 μg of the desired plasmid using
the Lipofectamine LTX with Plus reagent (ThermoFisher Scientiﬁc) ac-
cording to the manufacturer's instructions. 24 h later, cells were select-
ed by a treatment with G-418 (1 mg·mL−1) (Roche).
2.3. Generation of TSC2 KO cells via the CRISPR system
Lentiviral plasmid targeting human TSC2 gene via CRISPR systemwas
purchased from Sigma-Aldrich (pLenti U6gRNA TSC2-Cas9: Sigma-
Aldrich HS0000020001 and HS0000019924) as well as the non-target
guide (pLenti CRISPR-NT CONTROL: Sigma-Aldrich, CRISPR13-1EA).
Guides will be referred lately as TSC2 #1, #2 and N.Targ, respectively.
Brieﬂy, Lenti-X 293T cells (Clontech) were co-transfected together with
pLenti U6gRNA TSC2-Cas9 or pLenti CRISPR-NT CONTROL and pSPAX2-
D64A (Addgene plasmid 12260 modiﬁed in order to mutate HIV-1
integrase catalytic site, non-integrative vector) or pSPAX2 (integrative
vector) and a VSV-G encoding plasmids [29]. Lentiviral supernatants
were collected 48 h, 72 h and 96 h post-transfection, ﬁltrated and concen-
trated 100×by ultracentrifugation. The lentiviral vectorswere then titrat-
ed with qPCR Lentivirus Titration (Titer) Kit (ABM, LV900) and used for
cells transduction. After 72 h of transduction, cells expressing GFP were
isolated by FACS. Each clone was allowed to grow and later tested by
western blotting analysis and clones that were shown depleted for TSC2were selected. For non-integrative clones a second FACS analysis was
done after 2 weeks of culture in order to remove GFP expressing cells
(rare event of integration of CAS9 DNA sequence). For integrative clones,
cells were subjected to a regular puromycin treatment (5 μg·mL−1)
(Invivogen).
2.4. Establishment of stables transduced cell lines
peGFP-RIP3 WT, RIP3 KD (D161N) (Kinase Dead) and RIP3 RHIM/
AAAA (here after referred to as RHIMm) which were a kind gift from
FK. Chan, were subjected to PCRs where 3XFLAG tag was added at the
N-terminal part. 3XFLAG-RIP3-eGFPs amplicons were then cloned via
the Gateway Cloning system (ThermoFisher Scientiﬁc) into a pLenti
PGK Blast Dest plasmid (Addgene, 19065) [30] provided by the Dr.
Eric Campeau (University of Massachusetts Medical School). LN-18
cells were infected and stable pools of cells expressing 3XFLAG-RIP3-
eGFP selected with a blasticidin treatment (10 μg·mL−1) (Invivogen).
2.5. Puriﬁcation of RIP3 immuno-complex
3XFLAG-RIP3-eGFP WT LN-18 transduced cells' proteins were ex-
tracted with a lysis buffer (20 mM Tris-HCl pH 7,4; 1% Triton X-100;
10% glycerol; 150 mM NaCl; 1 mM PMSF; 3.3 mM NaF, 1 mM Na3VO4,
25 mM glycerol-phosphate, Roche Complete™ protease inhibitor
(Roche Life Science)). Incubated 20min on ice, lysates were centrifuged
at 15,000g for 15 min. The supernatant was collected and 56 mg of pro-
teins was pre-cleared for 4 h at 4 °C with 100 μL of Protein-G beads
(Santa Cruz Biotechnology, Dallas, TX), then incubated with 120 μL of
FLAG-M2 beads (Sigma-Aldrich) overnight at 4 °C. Beads were then
loaded on Poly-Prep Chromatography Columns (Bio-Rad) and washed
with 50 mL of wash buffer (400 mM NaCl lysis buffer) and eluted with
4 mL of elution buffer (20 mM Tris-HCl pH 7,4; 150 mM NaCl;
200 μg·mL−1 of 3XFLAG peptide (Sigma-Aldrich)). The eluted proteins
were concentrated on Vivaspin 500 columns (Sartorius) and resolved
on a 4–12% SDS-PAGE (Invitrogen). The gel was ﬁnally analyzed with
Sypro ruby staining (Invitrogen).
2.6. In-gel digestion and mass spectrometry (MS) analysis
In-gel digestion was performed by addition of modiﬁed trypsin
(Promega,Madison,WI) in 50mMammoniumbicarbonate at 37 °C over-
night. The tryptic digests were air dried and then dissolved in formic acid
(0.1%) for furtherMS-MS analysis. Each in-gel digest of an individual band
was analyzed by nano-high-performance liquid chromatography (HPLC)
electrospray MS-MS using an XCT ion trap mass spectrometer (Agilent,
Santa Clara, CA). The HPLC separations were performed on an RP C18
Zorbax column from Agilent. The mobile phase was a 90 min gradient
mixture formed as follows: mixture A, water-acetonitrile-formic acid
(97/3/0.1 [v/v/v]); mixture B, acetonitrile-water-formic acid (90/10/0.1
[v/v/v]). The ﬂow rate was ﬁxed at 300 nL/min. The collision energy
was set automatically depending on the mass of the parent ion. Each
MS full scan was followed by MS-MS scans of the ﬁrst four most intense
peaks detected in the prior MS scan. A list of peptide masses was subse-
quently introduced into the database for protein identiﬁcation searches
using MASCOT (Matrix Sciences).
2.7. Reagents and antibodies
5-Aminolevulinic acid (5-ALA) and p38 inhibitor (S8307) was pur-
chased from Sigma-Aldrich. MK2 inhibitor (MK2i, 475864) was bought
from Merck Millipore. TNF-α was from Peprotech and zVAD-fmk was
purchased from Promega. The BV6 Smac mimetic was previously de-
scribed [21]. The following antibodies were used for western blot analy-
sis: anti-FLAG-M2 (F-3165) and anti-RIP3 rat (R4277) (Sigma-Aldrich);
anti-Caspase-8 (ALX-804-429) and anti-LC3 (NT-0231-100) (Enzo Life
Sciences); anti-RIP1 (3493), anti-RIP3 human (13526), anti-TSC2
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(Thr37/46) (236B4) and anti-Phospho-p38 MAPK (Thr180/Tyr182)
(9211) (Cell Signalling Technology), anti-ATG7 (sc-12497), anti-YWHAE
(sc-23957), anti-YWHAZ (sc-1019), anti-MK2 (sc-6221), anti-HA probe
(sc-7392) (Santa Cruz Biotechnology); anti-Tuberin phospho S1254
human (ab133454) (Abcam); anti-GAPDH (AM4300) (Ambion).
2.8. PDT treatment
Cells were grown to 80% of conﬂuence They were treated with
0.5 mM 5-ALA (Sigma) diluted in a free-phenol red complete growth
medium for 3 h prior to irradiation with white light delivered by four
ﬂuorescent tubes (Aquarelle TLD-15W, Philips) with an irradiance of
23.70W·m−2 and a light dose of 2.13 J cm−2. Cells irradiationwas per-
formed in the free phenol red completemedium andwas then collected
and analyzed at the indicated time post-irradiation (pi).
2.9. RNAi transfection
A pool of four RNAi duplexes (smartpool) targeting human RIP3 (M-
003534-01-0005), TSC2 (M-003029-03-0005), MK2 (M-003516-02-
0005) andATG7 (M-020112-01-0005)were purchased fromDharmacon.
RNAi against humanYWHAZwasdesignedwith theBLOCK-iT™RNAiDe-
signer tools (Invitrogen) (5′-AGTTCTTGATCCCCAATGC-3′). Control RNAi
was purchased fromApplied Biosystems. RNAiswere used at a concentra-
tion of 50 nM and transfection performed using calcium phosphate
(ProFection® Mammalian Transfection System, Promega).
2.10. Confocal imaging and immunoﬂuorescence
Cellswereﬁxedwith4% (w/v) paraformaldehyde for 10min at room
temperature at the indicated times post-PDT. They were then perme-
abilized with 0.1% Triton X-100 PBS (Sigma-Aldrich) for 10 min at
room temperature and saturated for 1 h in PBS supplemented with 4%
of BSA. HA antibody was then incubated for overnight at 4 °C. Later,
slides were rinsed with PBS and incubated with Alexa secondary anti-
body (Invitrogen) for 1 h at room temperature. Cells were then washed
with PBS and stained with Hoechst33342 (Acros Organics) 1/50,000.
After water rinsing, slides were mounted with mowiol. Samples were
analyzed using a Leica TCS SP5 confocal microscope (Leica).
2.11. Western blot analysis
Western blotswere performed on the indicated extract. Total lysates
were obtained by resuspension of cells in total lysis buffer (50mMTris-
HCl pH 7.5, 150 mM NaCl, 1% Na-deoxycholate, 1% NP-40, 1 mM PMSF,
Roche complete protease inhibitor and Halt™ Phosphatase Inhibitor
cocktail (ThermoFisher)). The western blot procedure has been previ-
ously published [31].
2.12. Co-immunoprecipitation experiments
Brieﬂy, cells were lysed in the IP buffer (40 mM HEPES-HCl pH 7.4,
150 mM NaCl, 1% Triton X-100, 5% glycerol, 1 mMMgCl2, 1 mM PMSF,
Roche complete protease inhibitor and Halt™ Phosphatase Inhibitor
cocktail (ThermoFisher)) and about 1 mg of protein was precleared at
4 °C for 1 h with A/G magnetic beads (ThermoFisher) while target or
control antibody was incubated 1 h with the beads at room tempera-
ture. Cell lysates were then incubated with antibody coupled beads
4 h at 4 °C. Beads were then washed ﬁve times with the wash buffer
(450 mM NaCl IP buffer). Immunoprecipitates were then eluted for
10 min on ice with a 2% sodium dodecylsulfate (SDS) solution supple-
mented by 2× loading buffer (10mMTris-HCl pH6,8; 1% SDS; 25% glyc-
erol; 0,1mM β-mercaptoethanol; 0,03% bromophenol blue) and loaded
onto SDS-PAGE.2.13. Necrosis measurement
Lactate dehydrogenase (LDH) release essay was performed as
described previously [21]. Brieﬂy, LDH enzyme released by
necroptosis was measurement of the LDH enzyme activity in the
cell supernatant. Propidium iodide incorporation cell death assay
was conducted according the manufacturer procedure (Sigma). To
summarize, cells were trypsinized, washed with PBS then stained
with a 40 μg·mL−1 of propidium iodide solution (Sigma) and ﬁnally
analyzed by FACS.
2.14. Quantiﬁcation, signiﬁcance and statistical analysis
Western blots quantiﬁcationswere done using the “ImageQuant LAS
4000” software (GE). Observations exposed represent at least three in-
dependent experiments. Data are presented as mean ± SEM and were
analyzed with the GraphPad Prism software. Statistical signiﬁcance
was determined using the speciﬁed test. p ≤ 0.05 was considered
signiﬁcant.
3. Results
3.1. TSC2 promotes survival in glioblastoma after a 5-ALA-PDT treatment
As previously mentioned, glioblastoma cells undergo cytoprotective
autophagy following 5-ALA-PDT [14]. In the study of the upstream au-
tophagy regulators potentially involved in this process, we found that
siRNA-mediated silencing of TSC2 sensitized LN-18 glioblastoma cells
to 5-ALA-PDT treatment (Fig. 1A). To validate our observation, we gen-
erated TSC2 knock out LN-18 cell lines using the CRISPR/Cas9 technolo-
gy. The TSC2 knocked-out cells were more sensitive to induction of PDT
mediated cell death, indicating that TSC2might have a pro-survival role
in these cells (Fig. 1B). We conﬁrmed these ﬁndings by looking at addi-
tional glioma cell lines andwe found that in the absence of TSC2, surviv-
al U87, T98G and U373 cells were signiﬁcantly decreased following 5-
ALA-PDT treatment (Fig. 1C). Altogether, these analyses strongly indi-
cate that TSC2 might protect glioblastoma cells from 5-ALA-PDT-
induced cell death.
3.2. TSC2 binds YWHAZ upon a phosphorylation of S1254 by MK2
While investigating the molecular mechanisms underlying the
pro-survival function of TSC2 during PDT, we found that phosphory-
lation of TSC2 serine 1254 was induced by PDT treatment (Fig. 2A).
Interestingly, this serine is known to potentially regulate the mTOR
complex when being phosphorylated [32,33]. Closer examination
revealed that phosphorylation of S1254 follows a biphasic kinetic:
a ﬁrst increase occurred as early as 15 min post-PDT. This level of
S1254 phosphorylation is maintained up to 2 h post-treatment,
at which it underwent a second increase and reached a maximum
4 h post-irradiation as presented by our quantiﬁcation analysis
(Fig. 2B). When looking at TSC2 amino-acid sequence, we found
that S1254 lies within a canonical binding site for 14-3-3 proteins
(R/KXXS/TXP) [32]. Therefore, we decided to investigate the forma-
tion of a TSC2/14-3-3 complex during PDT. Because high levels of
YWHAZ (14-3-3 ξ) in glioblastoma tumors correlate with poor
patient prognosis [34], we decided to focus our attention on this
particular member of the 14-3-3 family. Co-immunoprecipitation
analysis showed that TSC2 associated with YWHAZ following
induction of PDT (Fig. 2A). In addition, PDT-induced TSC2/YWHAZ
interaction was conﬁrmed endogenously (Fig. 2C). Interestingly,
association between TSC2 and YWHAZ correlates with elevated
levels of S1254 phosphorylation. Co-immunoprecipitation experi-
ments between wt and S1254 phosphorylation mutants of TSC2
revealed that interaction with YWHAZ relies on the presence of a
phosphorylatable serine at position1254 (Fig. 2D). In agreement
Fig. 1. TSC2 protects glioblastoma from 5-ALA-PDT-induced cell death. (A) LN-18 were transfected with smartpool targeting TSC2 was used to silence hTSC2 (n = 6). Cell death was
measured by lactate dehydrogenase (LDH) release and propidium iodide incorporation assays compared to RNAi control (si CTR) at different time post-irradiation. Protein expression
depletion was evaluated by western blotting analysis on total lysate of untransfected cells (/), RNAi control transfected cells and target protein RNAi transfected cells and were
harvested at 4 h post-irradiation. GAPDH is a loading control. (B) LN-18 non-stably transduced by CRISPR cas9 guide Non Target (N.Targ.) or targeting TSC2 (TSC2 #2) were subjected
to PDT and cell death was measured by the LDH release and propidium iodide incorporation assays at the indicated times post-irradiation (pi). TSC2 protein expression level was
analyzed by western blotting. GAPDH was used as loading control (n = 3). (C) LN-18, U87, T98, and U373 glioma cells were transfected with RNAi control (si CTR) or TSC2 smartpool
(si TSC2) and were subjected to PDT. Cell death was measured by LDH release assay at the indicated time post-irradiation. TSC2 protein expression level was analyzed by western
blotting and GAPDH used as loading control (n= 3). (n= x, number of independent experiments; NT= untreated; pi= time post-irradiation; *p b 0.05, **p b 0.01, ***p b 0.001, t-test.)
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+2 relative to S1254 (P1256). Interestingly, mutation of this proline
into alanine abolished both interaction with YWHAZ and phosphor-
ylation of Ser1254 (Fig. 2D). These observations suggest that
association with YWHAZ might protect S1254 from dephosphoryla-
tion, as previously described for other 14-3-3 targets [35,36].
Supporting this, we found that preventing binding of YWHAZ by
incubation of cell lysate with an R18 peptide, a well-described
antagonist of 14-3-3s [37] decreases the level of S1254 phosphoryla-
tion (Fig. 2E).
MAPKAPK2 (MK2) has been reported to phosphorylate TSC2 on ser-
ine 1254 [38]. Accordingly, treatment with an MK2 inhibitor (MK2
Inhib, CAS 1186648-22-5) prevented PDT-induced TSC2 S1254 phos-
phorylation and interaction with YWHAZ (Fig. 2F). MK2 is a down-
stream kinase of p38 MAPK, known to be activated after PDT [39].
Therefore we studied p38 activation in our model. By looking at phos-
phorylation of Thr180/Tyr182 within p38 regulatory sites we found
that p38 was activated 4 h post-treatment, suggesting that a p38/MK2
axis is activated after 5-ALA-PDT in glioblastomas (Fig. 2G).3.3. Phosphorylation of TSC2 S1254 by MK2 constitutes a pro-survival axis
after 5-ALA-PDT
To investigate the relevance of TSC2 S1254 phosphorylation during
5-ALA-PDT, we ﬁrst knocked down expression of MK2 by RNAi
(Fig. 3A) or inhibited its activity using a small molecule inhibitor
(Fig. 3B). Both approaches signiﬁcantly increased the sensitivity of LN-
18 cells towards PDT treatment. In addition, inhibition of the MK2-
activating kinase p38 also led to a reduction in LN-18 cell survival fol-
lowing PDT (Fig. 3C). The above observations suggested that phosphor-
ylation of TSC2 by the p38/MK2 axis is important for TSC2 protective
function during PDT. Since we showed that phosphorylation of S1254
promotes recruitment of YWHAZ, we decided to investigate the role of
YWHAZ during PDT. Knocking down expression of YWHAZ by RNAi re-
sulted in increased cell death after PDT, supporting the idea that phos-
phorylation of TSC2 S1254 and concomitant recruitment of YWHAZ
are important for the protective function during PDT (Fig. 3D). To test
this hypothesis, we expressed wt or S1254 phosphorylation mutants
of TSC2 in the TSC2 KO LN-18 cells (Fig. 3E). As expected, expression
Fig. 2. TSC2 serine 1254 is phosphorylated by MK2 and binds YWHAZ after 5-ALA-PDT. (A) LN-18 cells were stably transfected with empty vector (EV) or by 3xHA-TSC2 (rat) wild type
(wt). Cells were then treated by PDT and harvested at the indicated time post-irradiation and lysates subjected to an HA immunoprecipitation. Eluates were loaded on SDS-PAGE for
western blotting analysis with TSC2 pS1254, HA or YWHAZ antibodies. (B) Relative quantiﬁcation of TSC2 S1254A phosphorylation signal of the above experiment compared to
untreated condition (n = 3). (C) LN-18 cells were treated by PDT and harvested at 4 h post-irradiation and lysates subjected to an TSC2 or control IgG immunoprecipitation. Eluates
were loaded on SDS-PAGE for western blotting analysis with TSC2 and YWHAZ antibodies. (D) LN-18 cells were stably transfected with an empty vector (EV) or 3xHA-TSC2 (rat) wild
type (wt), S1254A and P12565A and selected. Cells were then treated by PDT and lysates subjected to an HA immunoprecipitation. Eluates were loaded on SDS-PAGE for western
blotting analysis with TSC2 pS1254, HA, or YWHAZ antibodies. (E) LN-18 cells were stably transfected by 3xHA-TSC2 (rat) wild type (wt). Cells were treated by PDT and lysates
incubated with the R18 peptide (25 μM) for the indicated time (TI). Then, they were submitted to an HA immunoprecipitation and the eluate was loaded on SDS-PAGE for western
blotting analysis with TSC2 pS1254, HA, YWHAZ antibodies. (F) LN-18 cells were stably transfected with empty vector (EV) or by 3xHA-TSC2 (rat) wild type (wt) or S1254A. Cells
were then treated by PDT in presence of MK2 inhibitor (MK2 Inhib, 10 μM) and lysates subjected to an HA immunoprecipitation. Eluates were loaded on SDS-PAGE for western
blotting analysis with TSC2 pS1254, HA, or YWHAZ antibodies. (G) LN-18 cells were harvested 4 h post-irradiation. Total lysates were analyzed by western blotting with a p38
pThr180/Tyr182 antibody, GAPDH was used as loading control. (IP = immunoprecipitation; pi = time post-irradiation; NT = non-treated.)
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8 h after PDT treatment. In contrast expression of hTSC2 S1254A or
P1256A was unable to compensate for the absence of endogenous
TSC2. Interestingly, expression of S1254 in the TSC2 null-background
further promoted PDT-induced cell death. Altogether, these results
demonstrate that TSC2 prevents PDT-induced cell death in glioblastoma
cells, through a mechanism that relies on S1254 phosphorylation-
mediated recruitment of YWHAZ.
Because we previously published that glioblastoma cells treated
with 5-ALA-PDT activate a protective autophagic pathway [14], we test-
ed the potential role of TSC2 in this process using our TSC2 mutants
expressing cells lines. As expected, cells expressing wt hTSC2 increased
by 5-fold their LC3-I-to LC3-II conversion after PDT treatment. In
contrast, cells expressing hTSC2 S1254A and P1256A did not show any
increase in autophagy ﬂuxes (Fig. 3F). Interestingly, mTOR activity, as
assessed by phosphorylation of its downstream target 4EB-P1 was
dramatically increased in S1254 and P1256 mutant expressing cells, as
compared to cells expressing wt TSC2 (Fig. 3F). Finally, RNAi knock-
down of ATG7 which abolishes the basal and the induced macro-
autophagy, strongly increases the PDT-induced cell death in EV, hTSC2Wt, S1254 and P1256A expressing cells. Intriguingly, a higher cell
death induction was observed in EV, hTSC2 S1254 and P1256A
compared to hTSC2 wt expressing cells. The latest suggesting that
TSC2 serine 1254 phosphorylation might protect glioma from PDT
through multiple mechanisms including autophagy. Altogether these
data strongly support the idea that the ability of TSC2 to promote induc-
tion of autophagy and cell survival after 5-ALA-PDT relies on phosphor-
ylation of its serine 1254 and recruitment of YWHAZ.3.4. RIP3 forms a protein complex with RIP1, TSC2 and YWHAZ in
glioblastoma after 5-ALA-PDT
Asmentioned above, RIP3 is a key protein of the programmed necro-
sis pathway. RIP3 is activated and promotes cell death in glioblastoma
after 5-ALA-PDT [21]. Therefore, we were interested to know if there
was a crosstalk between the above described TSC2-dependent survival
events and the RIP3-mediated cell death pathway. Moreover, YWHAZ
and TSC2 have been found in two high throughput studies to potentially
interact with RIP3 [40,41].
Fig. 3. Phosphorylation of TSC2 serine 1254 promotes survival through the activation of autophagy after 5-ALA-PDT. (A and D) LN-18 indicated proteins were silenced and cell deathmeasured
by lactate dehydrogenase (LDH) release assay compare to RNAi control (si CTR) at different time post-irradiation. Protein expression depletionwas evaluated by a western blotting analysis on
total lysate of untransfected cells (/), RNAi control transfected cells and target protein RNAi transfected cells and harvested at 4 h post-irradiation. GAPDH is a loading control. (A) LN-18 were
transfectedwith aMK2 smart-pool targeting hMK2 (si MK2) and subjected to PDT (n=3).MK2 protein expression level was analyzed bywestern blotting and HSP90 used as loading control.
LN-18 cells were treated byMK2 (B) or p38 (C) inhibitors and cell deathmeasured by LDH release assay at the indicated times post-irradiation (n= 3). (D) LN-18were transfectedwith RNAi
targeting YWHAZ to silence hYWHAZ (n= 3). Protein extinction was analyzed bywestern blotting, GAPDH is a loading control. (E) LN-18were transduced and selected for 3xFlag-RIP3-eGFP
wt. Cells were then transduced by CRISPR Cas9 TSC2 targeting non integrative vector (TSC2 #2). Cells were then stably transfected with an empty vector (EV) or by 3xHA-TSC2 (human) wild
type (wt), S1254A andP12565A. Cellswere then subjected to PDT and cell deathwasmeasured by LDH release assay at the indicated timepost-irradiation (n=3).HA-TSC2 proteins expression
levelwas analyzed bywestern blottingwith anHAantibody andGAPDHused as loading control. (F) LN-18 3xFlag-RIP3-eGFP, endogenous TSC2 knockout expressing 3xHA-TSC2 (human)wild
type (wt), S1254A and P12565A (see above)were treated by PDT and harvested 4 h post-irradiation. Total lysateswere loaded on SDS-PAGE and analyzed bywestern blottingwith HA and the
indicated antibodies (upper panel). Representative LC3-II/LC3-I ratiowas quantiﬁed and analyzed (lower panel). (G) LN-18 3xFlag-RIP3-eGFP, endogenous TSC2 knockout expressing EV, 3xHA-
TSC2 (human)wild type (wt), S1254A and P12565A (see above)were silenced for human ATG7 protein. Cell deathwas thenmeasured by lactate dehydrogenase (LDH) release assay compare
to si CTR 8 h post-irradiation. Protein expression depletionwas evaluated by awestern blotting analysis on total lysate of untransfected cells (/), RNAi control transfected cells and target protein
RNAi transfected cells. GAPDH is a loading control (n= 4). (n= x, number of independent experiments; NT= non-treated; IP = immunoprecipitation; pi = time post-irradiation; *p b 0.05,
**p b 0.01, ***p b 0.001, t-test.)
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We ﬁrst transduced LN-18 glioblastoma cell line with hRIP3 tagged
with 3xFlag- at the N-terminus and eGFP at the C-terminus. Then,
we checked if tagged-RIP3 was able to form the classic necroptotic
complex with RIP1 and the caspase-8 upon a combined treatment
of TNF-α, Smac-mimetic and z-VAD-fmk (TSzvD) [27]; and con-
ﬁrmed the formation of RIP3 clusters after 5-ALA-PDT and TSzvD
treatments by confocal microscopy as showed previously [21,42]
(Supplementary Fig. S1).
Secondly, we performed a proteomic analysis on the eluate of a
3xFlag-RIP3-eGFP immunoprecipitate harvested 4 h post-irradiation
or in untreated condition (Fig. 4A). More than one hundred hits were
found (Supplementary Table S1), and among them YWHAE, a 14-3-3
protein.
Based on our own observation that TSC2 interacts with 14-3-3 pro-
teins, we investigated the potential interaction between RIP3, the 14-
3-3s and TSC2. We ﬁrst validated the new interactions of YWHAE,
YWHAZ and TSC2 with RIP3 in our over-expression model by co-
immunoprecipitation experiments at 4 h after treatment. RIP1 was
used as RIP3 complex induction control (Fig. 4B). Surprisingly, RIP3 in-
teracts stronger with TSC2 in treated conditions than in untreated
cells whereas YWHAZ only interacts with RIP3 after PDT treatment. In-
terestingly, TSC2/RIP3 and RIP3/YWHAZ PDT-induced interactionswere
conﬁrmed in a rat F98 glioblastoma cell line endogenous model
(Fig. 4C). We next performed an immunoﬂuorescence experiment and
observed a diffused localization of RIP3 and TSC2 in untreated cells
and a nucleation concomitant to a co-localization of both proteins 4 h
after PDT (Fig. 4D). This observation supports the hypothesis of a
TSC2/RIP3 complex formation after PDT. Unexpectedly, it is to notice
that TSC2 total protein expression was perturbed by PDT as assessed
bywestern blot analysis at different time point after PDT treatment. Ac-
tually, TSC2 protein level was signiﬁcantly decreased starting from 2 h
following PDT and returned to basal level 24 h after the treatment. To
the contrary, RIP3 and YWHAZ protein levelswere not affected (Supple-
mentary Fig. S2). Finally as previously showed [21], we conﬁrmed RIP3
implication in the glioblastoma cell deathmechanismusing RNAiwhere
RIP3 silencing correlated with decreased PDT-induced cell death
(Fig. 4E). Intriguingly, RIP3 is the only pro-death protein in the TSC2/
YWHAZ/RIP3 complex, but it is to notice that TSC2 cell death sensitivity
was not correlated to the expression level of RIP3 protein as shown by
western blots analysis in different glioma cell lines (Supplementary
Fig. S3).3.5. TSC2/RIP3/14-3-3 complex stoichiometry is affected by RIP3 KD and
RHIM mutations
RIP3 is a Serine/Threonine kinase and is able to form amyloid-like
structure with its RHIM (RIP Homotypic Interacting Motif) domain, lo-
calized in its C-terminal part [42]. Therefore we checked the inﬂuence
of KD (Kinase Dead) and RHIM (RIP Homotypic Interacting Motif)
RIP3 mutations, respectively abrogating the kinase activity of RIP3 and
its ability to multimerize with RIP1 after PDT, as previously described
[31]. By TSC2 immunoprecipitation, we showed that RIP3-KD mutant
was poorly recruited to TSC2 while the RHIM mutant interaction with
TSC2 was enhanced compared to RIP3-wt. Inhibition of RIP1 kinase ac-
tivity by necrostatin-1 does not interfere with the RIP3/TSC2 complex
stoichiometry, demonstrating that RIP kinase 1 activity is not required
for the formation of the RIP3 kinase containing complex (data not
shown). YWHAZ was recruited to TSC2 after PDT treatment as well,
with an interaction enhancement in the RIP3-RHIM condition
(Fig. 4F). Intriguingly, YWHAZ immunoprecipitation showed its robust
interaction with RIP3 wt after PDT and, respectively a decrease and an
enhancement of its interactions with RIP3-KD and RIP3-RHIM
(Fig. 4F). Together, these data suggest that TSC2 might interact with
RIP3 through multiple interfaces.3.6. RIP3/TSC2 interaction is modulated by TSC2 S1254 phosphorylation
As we identify S1254 of TSC2 as key of TSC2-mediated survival after
PDT, we next asked whether RIP3 preferentially interacted with S1254
phosphorylated version of TSC2. Interestingly, TSC2 phosphorylated on
serine 1254 strongly interactedwith RIP3 (Fig. 5A). On top of that, the sig-
nal level of TSC2 phosphorylated on serine 1254 is similar in both RIP3
and TSC2 immunoprecipitates suggesting that themajority of TSC2 phos-
phorylated on S1254 interacts with RIP3 (Fig. 5A). To better understand
the underlying mechanisms, we wondered whether phosphorylation of
S1254 of TSC2 would be involved in the regulation of its interaction
with RIP3. Thenweﬁrst carried out co-immunoprecipitation experiments
between rTSC2 wt, S1254A and P1256Amutants of TSC2 and RIP3. Inter-
estingly, after PDT, interactions with RIP3 were signiﬁcantly increased
with both TSC2 mutants than with the wild type, suggesting that phos-
phorylation of S1254 might interfere with RIP3 binding (Fig. 5B and
Fig. 5C). Supporting this, we found that promoting dephosphorylation of
TSC2 S1254 by preventing YWHAZ binding with the R18 peptide in-
creased the TSC2/RIP3 interaction, both in untreated and PDT-treated ly-
sates (Fig. 5D). Finally, inhibition of the TSC2 S1254 MK2 kinase
signiﬁcantly enhances interaction between RIP3 and TSC2 after PDT
(Fig. 5E and Fig. 5F). As expected, the recruitment of S1254 phosphorylat-
ed TSC2onRIP3 is affectedbyMK2 inhibitor treatment as shownbyquan-
tiﬁcation analysis of the ratio between S1254 phosphorylated TSC2 and
total TSC2 recruited to RIP3 (Fig. 5G). This observation strengthens our
hypothesis where RIP3 interacts with the whole available pool of S1254
phosphorylated form of TSC2. Altogether, these observations suggest
that through recruitment of YWHAZ, phosphorylation of TSC2 S1254 by
MK2 regulates the interaction between RIP3 and TSC2.
3.7. RIP3 binds stronger YWHAZ if TSC2 is inactive
YWHAZ is recruited to TSC2 under the phosphorylation of S1254
by MK2. Studying RIP3-immunocomplex in presence of MK2 kinase
inhibitor after PDT, we were interested to know if YWHAZ/RIP3 in-
teraction would be modulated by this small molecule. Interestingly,
we found that as TSC2, YWHAZ is strongly recruited to RIP3 than in
the control condition (Fig. 5E), suggesting that YWHAZ better inter-
acts with RIP3 when TSC2 is not phosphorylated on serine 1254 and
is not able to recruit YWHAZ, as demonstrated above. Finally, we
wondered about the origin of YWHAZ interaction with RIP3. For
this, we generated TSC2 KO LN-18 with the CRISPR/Cas 9 technology
and transduced them with tagged-RIP3. Surprisingly, the absence of
TSC2 does not affect the formation YWHAZ/RIP3 complex after PDT
(Fig. 5H). These data suggest that RIP3 recruitment of YWHAZ is in
competition with TSC2.
Altogether, we know that RIP3 is the only pro-death protein in the
TSC2/YWHAZ/RIP3 complex and its interaction with TSC2 and YWHAZ
seems to be precisely modulated by the critical pro-survival serine
1254 status. Moreover, our observations allowed us to propose that
RIP3 antagonizes with the TSC2-dependent pro-survival pathway via
dephosphorylation of TSC2 by competition for YWHAZ then the seques-
tration of TSC2 inactive forms.
4. Discussion
In this paper, using an unbiased proteomic approach, we have iden-
tiﬁed several new RIP3 partners involved in a pro-death complex and
shown that this complex pro-death activity is counter-balanced by a
TSC2/14-3-3s complex regulated via the p38 MAPK pathway. These re-
sults offer the ﬁrst characterization of a regulated necrosis pathway in-
duced in glioblastoma by an oxidative stress generated by PDT. This
model is quite unique since the induction of necrosis in glioblastoma
cells requires neither inhibition of capsase-8 activity nor the addition
of Smac mimetics.
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ferent cell line models [20,43,44]. Therefore, our observation that PDT
is able to induce necrosis in glioblastoma cells in vitro is quite unique
and translates perfectly with in vivo observations showing important
necrosis in treated tumors [23].
Since 2009, a canonical programmed necrosis pathway (necroptosis)
has been described with RIP3 and RIP1 kinases as central key proteins.
The signaling pathway triggered by TNF-α stimulation, requires Smacmi-
metic and pan-caspase inhibitors addition to induce a signiﬁcant
necroptotic cell death signal dependent on the formation of a RIP3/RIP1
complex [27]. Recently, other models of regulated necrosis involving or
not RIP3 and RIP1 have been described: ferroptosis, NETosis or CYPD-
dependent regulated necrosis [45]. Interestingly, our model of regulated
cell death induced by 5-aminolevulinic acid-based PDT in LN-18 glioblas-
toma cells can be considered as a rare cellularmodel where necroptosis is
triggered by a burst of ROS in mitochondria and via the activation of a
RIP3-containing complex, butwithout any additional apoptosis inhibitors.
In terms of activation, our glioblastomamodel of necroptosis seems to be
very relevant towhat is observed in vivo following PDT but also following
Ischemia/Reperfusion in the brain, heart and kidney [46].
Additionally, it is to notice that some groups described an autophagy-
dependent cell death induced by PDT [47,48]. Autophagy is still consid-
ered as a key pathway for cancer treatment and especially with PDT,
where it can lead primarily to a pro-survival pathway or in some circum-
stances to an autophagic cell-death induction [49,50]. In the case of glio-
blastoma, pro-autophagy drug treatments have been shown to
signiﬁcantly affect cell death [2] but this strategy cannot be applied to
5-ALA-PDT treatment of glioblastoma where the autophagy clearly pro-
tects glioblastoma and is suggested to eliminate PDT-damaged structures
and proteins [14].
Our aforementioned experimental results reveal two main events
appearing after 5-aminolevulinic acid-based PDT in glioblastoma cells.
Firstly, from early time points after irradiation, we described the activa-
tion of a p38/MK2/TSC2/14-3-3 axis leading to the activation of a pro-
survival autophagy. Secondly, at later time points, pro-death kinase
RIP3 interacts with TSC2 and 14-3-3 proteins to down-regulate the
above mentioned pro-survival action.
Role of p38 MAPK in cell survival after PDT-induced cell death is
currently controversial [51]. In our study, p38 is related to an MK2-
dependent phosphorylation of TSC2 serine 1254 which is suggested
to be a clear pro-survival axis to activate a salutary autophagy
which occurs as soon as 15 min after irradiation [14]. As we know
that TSC2 activity is generally down-regulated in glioblastoma by
upstream genetic alteration in the PI3K/AKT pathway [52], we were
surprised to observe a pro-survival role of TSC2 after PDT. In addi-
tion, oppositely to PDT-treated cells, the basal level of glioblastoma
cell death was not affected by the TSC2 or MK2 silencing indicating
that these pro-survival-related events only occurred in stressed
cells where the autophagy pathway is over-activated and mediates
survival [14].
TSC2 S1254 phosphorylation pattern along the time post-
irradiation is biphasic, which was unexpected. TSC2 is phosphorylat-
ed on serine 1254 from 15min to 6 h after irradiation upon p38/MK2Fig. 4. Formation of a TSC2/14-3-3/RIP3 protein complex after 5-ALA-PDT. (A) 56 mg of prote
irradiation and the immunoprecipitation done as described in the Materials and methods sect
post-irradiation. Lysates were then subjected to a Flag or control IgG immunoprecipitation.
YWHAE or YWHAZ antibodies. (C) F98 cells were treated PDT and harvested 4 h post-irradia
were loaded on SDS-PAGE for western blotting analysis with TSC2, RIP3, RIP1 or YWHAZ ant
TSC2 (human) wild type (wt), grown on coverslips and submitted to PDT treatment. Cells
analyzed with a confocal microscope. Hoechst was used to identify the nucleus. (E) A sma
measured by LDH release assay compare to RNAi control (si CTR) at different time post-irradi
lysate of untransfected cells (/), RNAi control transfected cells and target protein RNAi trans
(F) LN-18 were transduced by Flag-RIP3-eGFP wt, Kinase Dead mutant (KD) or RHIM muta
YWHAZ or control IgG immunoprecipitation and eluates loaded on SDS-PAGE for wester
immunoprecipitation; pi = time post-irradiation; Input = total lysate extract; ***p b 0.001, t-taxis activation with a peak 4 h post-treatment. At early stages, TSC2
activation seems to be a direct response to PDT-linked oxidative
stress. However, TSC2 late phosphorylation appears concomitantly
to RIP3-dependent cell death mechanisms activation as suggested
by our RNAi study which showed that RIP3 affects cell death re-
sponse only 4 h post-irradiation. This suggests that, at early time
points after irradiation, TSC2-dependent survival pathway is not
linked to the RIP3 cell death pathway by opposition to what is seen
at later time points where the TSC2 phosphorylated form appears
in a RIP3-containing complex mediating cell death activation.
Interestingly, our study precisely identiﬁed that MK2-dependent
phosphorylation of TSC2 serine 1254 is a major event of the TSC2-
dependent survival pathway. Moreover we showed that phosphoryla-
tion of this serine was directly linked to a pro-survival activation of au-
tophagy. This rise of autophagic ﬂux is suggested to be a consequence of
a decreased mTOR activity when TSC2 serine 1254 is phosphorylated. It
is to notice that only rare descriptions of TSC2 as a pro-survival factor
have been described, and only in models where the autophagy was
clearly identiﬁed as pro-survival [36].
From 15 min post-irradiation, we observed the formation of a com-
plex where 14-3-3 proteins bound to TSC2 on an interaction site based
on the phosphorylated serine 1254. In addition, we showed that 14-3-
3s recruitment protects the S1254 phosphorylation against phospha-
tases and subsequently protects the pro-survival autophagy activation.
Protective role of 14-3-3s was assessed by knock-down studies where
their silencing enhances the cell sensitivity to PDT-induced cell death.
This last observation was in accordance with previous studies in glio-
blastoma [34,53].
We know that RIP3 is the only pro-cell death protein in the TSC2/14-
3-3 complex which formation has been assessed 4 h post-irradiation.
Surprisingly, thewhole pool of S1254 phosphorylated TSC2 seems to in-
teract with RIP3. On the other hand, we described that TSC2 S1254
phosphorylation status is essential to activate the TSC2-dependent sur-
vival pathway, and seems to modulate TSC2/RIP3 complex stoichiome-
try. Concomitantly, we presented the recruitment of 14-3-3 proteins on
TSC2 as a protective event against the dephosphorylation of the critical
serine 1254. In addition, we showed that RIP3 binds strongly the 14-3-
3s when TSC2 is not phosphorylated, suggesting that RIP3 competes
with TSC2 for the binding of 14-3-3s.
So as a model, we propose that RIP3, by its competition mecha-
nism, promotes a diminution of the TSC2-survival signal by de-
creasing the 14-3-3 proteins pool bound to TSC2 phosphorylated
S1254 and so, inducing serine 1254 dephosphorylation. Finally,
we suggest that non-phosphorylated TSC2 pool is trapped by RIP3
to avoid MK2 reactivation as shown by a stronger interaction of
RIP3 with unphosphorylated form of TSC2. Our model is summa-
rized in Fig. 6.
Interplays between necroptosis and autophagy pathways have
been recently described. In particular, RIP3 has been identiﬁed to
promote an autophagic response against coxsackievirus B3 infection
in intestinal epithelial cells [54] or to directly interact with p62 [55]
and Atg5 [56]. In our study, we suggest that RIP3 can interact and in-
terfere with TSC2, another key player of the autophagic pathway.ins was extracted with the IP buffer of 3xFlag-RIP3-eGFP LN-18 cells, harvested 4 h post-
ion. (B) 3xFlag-RIP3-eGFP LN-18 transduced cells were treated by PDT and harvested 4 h
Eluates were loaded on SDS-PAGE for western blotting analysis with TSC2, Flag, RIP1,
tion. Lysates were then subjected to a RIP3 or control IgG immunoprecipitation. Eluates
ibodies. (D) LN-18 3XFlag-RIP3-eGFP transduced cells were stably transfected with HA-
were then ﬁxed, incubated with HA antibody. TSC2 and tagged-RIP3 localization was
rtpool targeting hRIP3 was used to silence RIP3 in LN-18 cells (n = 4). Cell death was
ation. Protein expression depletion was evaluated by a western blotting analysis on total
fected cells and harvested at the 4 h post-irradiation. GAPDH is used as loading control.
nt (RHIM) and harvested 4 h post-irradiation. Lysates were then subjected to a TSC2,
n blotting analysis with TSC2, Flag, or YWHAZ antibodies. (NT = non-treated; IP =
est.)
Fig. 5. TSC2 S1254 phosphorylationmodulates the RIP3/TSC2 interaction after PDT. (A) LN-18 cells transduced by 3xFlag-RIP3-eGFPwere treated by PDT and lysates subjected to a Flag or
TSC2 immunoprecipitation. Eluates were then loaded on SDS-PAGE for western blotting analysis with TSC2 pS1254, TSC2 and Flag antibodies. (B) LN-18 cells were transduced by 3xFlag-
RIP3-eGFP and stably transfected with an empty vector (EV) or by 3xHA-TSC2 (rat) wild type (wt), S1254A and P12565A. Cells were then treated by PDT and lysates subjected to an HA
immunoprecipitation. Eluates were loaded on SDS-PAGE for western blotting analysis with HA and Flag antibodies. (C) Quantiﬁcation and analysis of the RIP3/TSC2 ratio of the above HA
immunoprecipitation (n=3). (D) LN-18 cells transduced by 3xFlag-RIP3-eGFPwere treated by PDT and lysates incubatedwith R18 peptide (25 μM) during TSC2 immunoprecipation. IgG
immunoprecipitation was used as control. Eluates were then loaded on SDS-PAGE for western blotting analysis with TSC2, Flag and YWHAZ antibodies. (E) LN-18 cells transduced by
3xFlag-RIP3-eGFP were treated by PDT in the presence of MK2 inhibitor (MK2 Inhib, 10 μM) and lysates subjected to control IgG or Flag immunoprecipitation. Eluates were then
loaded on SDS-PAGE for western blotting analysis with TSC2 pS1254, TSC2, Flag and YWHAZ antibodies. (F) Quantiﬁcation and analysis of the TSC2/RIP3 ratio of the above Flag
immunoprecipitation (n = 3). (G) Quantiﬁcation and analysis of the ratio pTSC2/TSC2 immunoprecipitated with RIP3 (n = 3). (H) LN-18 was transduced by 3xFlag-RIP3-eGFP wt and
by CRISPR Cas9 integrative vectors: Non Target (N.Targ.), TSC2 #1 and #2. Cells were then treated by PDT and lysates subjected to a Flag or control IgG immunoprecipitation. Eluates
were loaded on SDS-PAGE forwestern blotting analysiswith TSC2, Flag or YWHAZantibodies. (n=x, number of independent experiments;NT=non-treated; IP= immunoprecipitation;
pi = time post-irradiation; ***p b 0.001, t-test.)
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Fig. 6. Proposed survival mechanisms occurring in glioblastoma after 5-ALA-PDT. After PDT, p38 is phosphorylated and activated together with its downstream kinase MK2. MK2 then
phosphorylates TSC2 on serine 1254 which recruits protective 14-3-3 proteins and promotes cell survival by the activation of the autophagy process. About 4 h post-treatment, cell
death inducer RIP3 is activated and interacts with S1254 phosphorylated TSC2 protein pool. By a competition mechanism for the TSC2 linked 14-3-3 proteins, RIP3 mediates
dephosphorylation of TSC2, traps the inactive TSC2 and thus down-regulates TSC2-dependent survival.
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p62 after PDT. This interaction is reinforced when cells are treated
with MK2 inhibitor (data not shown). These observations suggest
that RIP3 would potentially target several proteins in the autophagic
pathway, strengthening the idea that our cellular PDT system is po-
tentially interesting to study cross-talks between RIP3 and the au-
tophagy pathway.
From a clinical point of view, glioblastomas are currently still al-
most incurable. Current strategies only extend the patient lifetime
but without possibility to eradicate the tumors. We deﬁnitively
need fundamental research to discover new therapeutic approaches,
novel ideas and new pathways to target for the patient's beneﬁts.
Moreover, it is obvious that therapeutic strategies even in the PDT
ﬁeld have to be customized to the tumor speciﬁcity of each patient.
In the present study, we highlighted that pro-survival autophagy
and the 14-3-3 proteins family are strong potential targets to en-
hance glioblastoma sensitivity to anti-tumors therapies. Moreover
we clearly described MK2 and TSC2 as new potentials therapeutic
targets in glioblastoma treatment by 5-ALA-PDT.
In conclusion, we described a new TSC2-dependent survival pathway
which is triggered in glioblastoma in response to 5-aminolevulinic acid-
based PDT. Moreover, this pathway seems to be targeted by RIP3, which
binds TSC2 after PDT in order to fully induce necroptosis.
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